PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 180 participants.

Also called NCT07243119

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07243119
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07243119. Randomized; quadruple masking; primary purpose diagnostic. Start 2025-12-08 (actual); primary completion 2029-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure
Acronym
PRIMA-HF
Condition
Heart Failure and Reduced Ejection Fraction
Condition
Heart Failure
Intervention (Diagnostic test)
HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging
Intervention (Drug)
Two different doses of adenosine
Lead sponsor
Gødstrup Hospital (class: other)

Record details

Record id
cardio:ct-nct07243119
Content hash
430b0f79cd317614f1a4ba8959d12d7b92d9098aa81d29ca307117893de81bac